Table 2.
Genes encoding drug targets for FDA approved anti-RA drugs that appear in the network modules.
| Module | Drug target | Drug | Drug class |
|---|---|---|---|
| (2) | JAK1 | Tofacitinib | DMARDs |
| JAK2 | Tofacitinib | DMARDs | |
|
| |||
| (4) | IL1B | Canakinumab | Biotech agents |
| IL6R | Tocilizumab | Biotech agents | |
| LTA | Etanercept | Biotech agents | |
| TNF | Etanercept | Biotech agents | |
| Adalimumab | Biotech agents | ||
| Infliximab | Biotech agents | ||
| Golimumab | Biotech agents | ||
| Certolizumab pegol | Biotech agents | ||
| Chloroquine | DMARDs | ||
| TNFRSF1B | Etanercept | Biotech agents | |
|
| |||
| (5) | IL1R1 | Anakinra | Biotech agents |
|
| |||
| (6) | PTK2B | Leflunomide | DMARDs |
|
| |||
| (7) | MAPK3 | Sulindac | NSAIAs |
|
| |||
| (8) | CHUK | Sulfasalazine | DMARDs |
| IKBKB | Sulfasalazine | DMARDs | |
| Auranofin | DMARDs | ||
|
| |||
| (9) | PDPK1 | Celecoxib | NSAIAs |
|
| |||
| (10) | BCL2 | Ibuprofen | NSAIAs |